Acotiamide, a novel gastroprokinetic for the treatment of patients with functional dyspepsia: Postprandial distress syndrome

Expert Review of Gastroenterology and Hepatology

Volumn 6, Issue 5, 2012, Pages 533-544

  Altan, Ege ^a   Masaoka, Tatsuhiro ^a   Farré, Ricard ^a   Tack, Jan ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

acotiamide; early satiation; functional dyspepsia; gastric accommodation; gastric emptying; postprandial fullness; randomized controlled trial

Indexed keywords

ACETYLCHOLINE; ACETYLCHOLINESTERASE; ACOTIAMIDE; ITOPRIDE; MOSAPRIDE; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; PLACEBO; PROKINETIC AGENT;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ACETYLCHOLINE RELEASE; BLOATING; CLINICAL RESEARCH; DIARRHEA; DIZZINESS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; DRUG WITHDRAWAL; DUODENOGASTRIC REFLUX; DYSPEPSIA; ECHOGRAPHY; ENZYME INHIBITION; EPIGASTRIC FULLNESS; EUROPE; EXCITATORY JUNCTION POTENTIAL; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROINTESTINAL DISEASE; HEADACHE; HEARTBURN; HUMAN; INTESTINE INNERVATION; JAPAN; MAXIMUM PLASMA CONCENTRATION; NAUSEA AND VOMITING; NONHUMAN; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTPRANDIAL STATE; PROLACTIN BLOOD LEVEL; QT PROLONGATION; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR BINDING; RECEPTOR BLOCKING; REMISSION; REVIEW; RHINOPHARYNGITIS; SATIETY; SHORT FORM 36; SIDE EFFECT; STOMACH EMPTYING; STOMACH MOTILITY; STOMACH MUSCLE; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; UNITED STATES;

ANIMALS; BENZAMIDES; CLINICAL TRIALS AS TOPIC; DYSPEPSIA; HUMANS; POSTPRANDIAL PERIOD; THIAZOLES; TREATMENT OUTCOME;

EID: 84867551602     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/egh.12.34     Document Type: Review

References (37)

1. Piessevaux H, De Winter B, Louis E et al. Dyspeptic symptoms in the general population: A factor and cluster analysis of symptom groupings. Neurogastroenterol. Motil. 21(4), 378-388 (2009).
2. Tack J, Bisschops R, Sarnelli G. Pathophysiology and treatment of functional dyspepsia. Gastroenterology 127(4), 1239-1255 (2004). (Pubitemid 39345892)
3. Kindt S, Tack J. Impaired gastric accommodation and its role in dyspepsia. Gut 55(12), 1685-1691 (2006). (Pubitemid 44893562)
4. Van Oudenhove L, Vandenberghe J, Geeraerts B et al. Determinants of symptoms in functional dyspepsia: gastric sensorimotor function, psychosocial factors or somatisation? Gut 57(12), 1666-1673 (2008).
5. Kindt S, Van Oudenhove L, Mispelon L, Caenepeel P, Arts J, Tack J. Longitudinal and cross-sectional factors associated with long-term clinical course in functional dyspepsia: A 5-year follow-up study. Am. J. Gastroenterol. 106(2), 340-348 (2011).
6. Tack J, Janssen P. Emerging drugs for functional dyspepsia. Expert Opin. Emerg. Drugs 16(2), 283-292 (2011).
7. Talley NJ, Colin-Jones D, Koch KL, Nyren O, Stanghellini V. Functional dyspepsia. A classification with guidelines for diagnosis and management. Gastroenterol. Int. 4, 145-160 (1991).
8. Talley NJ, Stanghellini V, Heading RC, Koch KL, Malagelada JR, Tytgat GN. Functional gastroduodenal disorders. Gut. 45(Suppl. 2), II37-II42 (1999).
9. Tack J, Talley NJ, Camilleri M et al. Functional gastroduodenal disorders. Gastroenterology 130(5), 1466-1479 (2006).
10. Talley NJ, Ruff K, Jiang X, Jung HK. The Rome III Classification of dyspepsia: Will it help research? Dig. Dis. 26(3), 203-209 (2008). (Pubitemid 351667802)
11. Tack J, Masaoka T, Janssen P. Functional dyspepsia. Curr. Opin. Gastroenterol. 27(6), 549-557 (2011).
12. Hallerbäck BI, Bommelaer G, Bredberg E et al. Dose finding study of mosapride in functional dyspepsia: A placebo-controlled, randomized study. Aliment. Pharmacol. Ther. 16(5), 959-967 (2002). (Pubitemid 34461766)
13. Holtmann G, Talley NJ, Liebregts T, Adam B, Parow C. A placebo-controlled trial of itopride in functional dyspepsia. N. Engl. J. Med. 354(8), 832-840 (2006). (Pubitemid 43290921)
14. Talley NJ, Tack J, Ptak T, Gupta R, Giguère M. Itopride in functional dyspepsia: Results of two Phase III multicentre, randomised, double-blind, placebo-controlled trials. Gut 57(6), 740-746 (2008). (Pubitemid 351716964)
15. Ogishima M, Kaibara M, Ueki S, Kurimoto T, Taniyama K. Z-338 facilitates acetylcholine release from enteric neurons due to blockade of muscarinic autoreceptors in guinea pig stomach. J. Pharmacol. Exp. Ther. 294(1), 33-37 (2000). (Pubitemid 30434667)
16. Nakajima T, Nawata H, Ito Y. Z-338, a newly synthetized carboxyamide derivative, stimulates gastric motility through enhancing the excitatory neurotransmission. J. Smooth Muscle Res. 36(2), 69-81 (2000).
17. Doi Y, Murasaki O, Kaibara M et al. Characterization of functional effects of Z-338, a novel gastroprokinetic agent, on the muscarinic M1, M2, and M3 receptors expressed in Xenopus oocytes. Eur. J. Pharmacol. 505(1-3), 31-35 (2004). (Pubitemid 39535673)
18. Morita H, Abe K, Ito Y, Inoue R. Possible involvement of M5 muscarinic receptor in the enhancing actions of the novel gastroprokinetic agent Z-338 on nifedipine-sensitive voltage-dependent Ca2+ currents in guinea pig stomach. Jpn. J. Pharmacol. 89(4), 356-365 (2002). (Pubitemid 35021649)
19. Kawachi M, Matsunaga Y, Tanaka T et al. Acotiamide hydrochloride (Z-338) enhances gastric motility and emptying by inhibiting acetylcholinesterase activity in rats. Eur. J. Pharmacol. 666(1-3), 218-225 (2011).
20. Matsunaga Y, Tanaka T, Yoshinaga K et al. Acotiamide hydrochloride (Z-338), a new selective acetylcholinesterase inhibitor, enhances gastric motility without prolonging QT interval in dogs: Comparison with cisapride, itopride, and mosapride. J. Pharmacol. Exp. Ther. 336(3), 791-800 (2011).
21. Seto K, Sasaki T, Katsunuma K, Kobayashi N, Tanaka K, Tack J. Acotiamide hydrochloride (Z-338), a novel prokinetic agent, restores delayed gastric emptying and feeding inhibition induced by restraint stress in rats. Neurogastroenterol. Motil. 20(9), 1051-1059 (2008).
22. Kobayashi N, Seto K, Sasaki T, et al. Acotiamide (Z-338), a novel gastroprokinetic agent for the treatment of functional dyspepsia, restores delayed gastric emptying induced by restraint stress via the vagal afferent pathway in rats. Gastroenterology 140, S603-S603 (2011).
23. Price CJ, Hoyda TD, Ferguson AV. The area postrema: A brain monitor and integrator of systemic autonomic state. Neuroscientist 14(2), 182-194 (2008). (Pubitemid 351348111)
24. Kawachi M, Hori N, Takei M, Kurimoto T, Akaike N, Ito Y. Gastric relaxation induced by electrical and chemical stimulation of the area postrema in the rat. Gen. Physiol. Biophys. 27(4), 243-252 (2008).
25. Akaike H, Jang II, Hori N, Ogawa S, Ito Y, Akaike N. Effects of Z-338, a novel gastroprokinetic agent, on the actions of excitatory and inhibitory neurotransmitters on neurons in area postrema. J. Smooth Muscle Res. 46(1), 31-47 (2010).
26. Tack J, Masclee A, Heading R et al. A dose-ranging, placebo-controlled, pilot trial of acotiamide in patients with functional dyspepsia. Neurogastroenterol. Motil. 21(3), 272-280 (2009).
27. Oliver SD, Ward C, Ward J, Kato H, Saito Y, Furuta S. Z-338: Phase I, single and multiple oral dose, safety, tolerability and pharmacokinetic studies in healthy male subjects. Abstracts of the Joint Meeting of VII World Conference on Clinical Pharmacology and Therapeutics IUPHAR-Division of Clinical Pharmacology & 4th Congress of the European Association for Clinical Pharmacology and Therapeutics. 244 (2000).
28. Adam B, Liebregts T, Zschau NB, et al. Z-338 improves meal-induced symptoms in functional dyspepsia: A double-blind, randomized, placebo controlled crossover study. Gastroenterology 136, A535 (2009).
29. Kusunoki H, Haruma K, Manabe N et al. Therapeutic efficacy of acotiamide in patients with functional dyspepsia based on enhanced postprandial gastric accommodation and emptying: Randomized controlled study evaluation by real-time ultrasonography. Neurogastroenterol. Motil. 24(6), 540-545, e250 (2012).
30. Matsueda K, Hongo M, Sasaki D, et al. Therapeutic efficacy of novel agent (Z-338) in functional dyspepsia. Gastroenterology 128, A467 (2005).
31. Tack JF, Talley NJ, Kowalski DL, Borton MA, Barve A. Influence of PPI run-in, pH monitoring and nutrient tolerance on efficacy outcomes of acotiamide hydrochloride (YM443), a novel acetylcholine esterase inhibitor, in functional dyspepsia. Gastroenterology 134, A143 (2008).
32. Talley NJ, Tack JF, Kowalski DL, Borton MA, Barve A. A novel acetylcholine esterase inhibitor acotiamide hydrochloride (YM443) in functional dyspepsia: Efficacy in a randomized, double-blind, placebo-controlled dose ranging trial. Gastroenterology 134, A157-A158 (2008).
33. Matsueda K, Hongo M, Tack J, Aoki H, Saito Y, Kato H. Clinical trial: Dosedependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia-100 mg t.i.d. is an optimal dosage. Neurogastroenterol. Motil. 22(6), 618-e173 (2010).
34. Tack JF, Stanghellini V, Hohmann G, et al. Efficacy and safety study of acotiamide (Z-338) in European patients with functional dyspepsia. Gastroenterology 140, S805-S805 (2011).
35. Matsueda K, Hongo M, Tack J, Saito Y, Kato H. A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia. Gut 61(6), 821-828 (2012).
36. Matsueda K, Hongo M, Ushijima S, Akiho H. A long-term study of acotiamide in patients with functional dyspepsia: Results from an open-label Phase III trial in Japan on efficacy, safety and pattern of administration. Digestion 84(4), 261-268 (2011).
37. Suzuki H, Hibi T. Acotiamide (Z-338) as a possible candidate for the treatment of functional dyspepsia. Neurogastroenterol. Motil. 22(6), 595-599 (2010).